Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trialsEllen M. Apperloo, Hiddo J.L. Heerspink, Stefan D. Anker et al.|The Lancet Diabetes & Endocrinology|2024Cited by 135
EFFECTS OF SGLT2 INHIBITORS ON CARDIOVASCULAR OUTCOMES WITH AND WITHOUT BASELINE USE OF GLP-1 RECEPTOR AGONISTS: A SMART-C COLLABORATIVE META-ANALYSISBrendon L. Neuen, Hiddo J.L. Heerspink, Ellen M. Apperloo et al.|Journal of the American College of Cardiology|2024Cited by 1